ELVN 002
Alternative Names: ELVN-002Latest Information Update: 21 Aug 2024
At a glance
- Originator Enliven Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Colorectal cancer; HER2 positive breast cancer; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 07 Jun 2024 Phase-I clinical trials in Non-small cell lung cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Italy, France, Spain (PO) (NCT05650879)
- 07 Jun 2024 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Spain, Italy, France (PO) (NCT05650879)
- 26 Mar 2024 Phase-I clinical trials in Colorectal cancer (Combination therapy, Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT06328738)